BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 18619662)

  • 1. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
    Qamar L; Davis R; Anwar A; Behbakht K
    Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of melatonin on the proliferation and cis-diamminedichloroplatinum (CDDP) sensitivity of cultured human ovarian cancer cells.
    Futagami M; Sato S; Sakamoto T; Yokoyama Y; Saito Y
    Gynecol Oncol; 2001 Sep; 82(3):544-9. PubMed ID: 11520153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines.
    Xie XK; Yang DS; Ye ZM; Tao HM
    Chemotherapy; 2009; 55(6):433-40. PubMed ID: 19996588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeine induces S-phase apoptosis in cis-diamminedichloroplatinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M.
    Shinomiya N; Takemura T; Iwamoto K; Rokutanda M
    Cytometry; 1997 Apr; 27(4):365-73. PubMed ID: 9098629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
    Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
    Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death.
    Shinomiya N; Shinomiya M; Wakiyama H; Katsura Y; Rokutanda M
    Exp Cell Res; 1994 Feb; 210(2):236-42. PubMed ID: 8299722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
    Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
    Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.
    Ong PS; Wang XQ; Lin HS; Chan SY; Ho PC
    Int J Oncol; 2012 May; 40(5):1705-13. PubMed ID: 22328352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
    Yang XK; Wang JD; Wang SY; Zhang YX
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells.
    Kikuchi Y; Hirata J; Kita T; Imaizumi E; Tode T; Nagata I
    Gynecol Oncol; 1993 Jun; 49(3):365-72. PubMed ID: 8314539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II).
    Kikuchi Y; Hirata J; Hisano A; Tode T; Kita T; Nagata I
    Gynecol Oncol; 1995 Jul; 58(1):11-5. PubMed ID: 7789875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.
    Janss AJ; Levow C; Bernhard EJ; Muschel RJ; McKenna WG; Sutton L; Phillips PC
    Exp Cell Res; 1998 Aug; 243(1):29-38. PubMed ID: 9716446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints.
    Kohn EA; Yoo CJ; Eastman A
    Cancer Res; 2003 Jan; 63(1):31-5. PubMed ID: 12517773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.
    Zhang N; Wu ZM; McGowan E; Shi J; Hong ZB; Ding CW; Xia P; Di W
    Cancer Sci; 2009 Dec; 100(12):2459-64. PubMed ID: 19769630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.